This preclinical data strengthens Monte Rosa's QuEEN platform and validates CCNE1 as a druggable target, which could drive investor interest ahead of the IND filing. Traders should monitor for IND acceptance and Phase 1 trial initiation as next catalysts. Despite recent insider selling, the scientific differentiation may support positive sentiment in the near term.
Price Chart
Executive Summary
Monte Rosa Therapeutics announced promising preclinical data for its first-in-class CCNE1-directed molecular glue degrader, MRT-55811, showing deep tumor regressions in multiple CCNE1-amplified cancer models and superior selectivity over CDK2 inhibitors. The company plans to submit an IND to the FDA later this year, marking a key step toward clinical development. While the data support potential clinical benefit in high-unmet-need cancers, the results are preclinical and not yet tested in humans.
Key Facts
- MRT-55811 induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers
- Demonstrated superior selectivity vs. clinical-stage CDK2 inhibitors with no detectable off-target degradation of related cyclins or CDKs
- IND submission for MRT-55811 anticipated later in 2026
- Data to be presented at AACR Annual Meeting 2026 on April 21, 2026
- CCNE1 amplification is common in ovarian, endometrial, gastric, and breast cancers and has been historically undruggable
Financial Impact
No direct financial impact disclosed; potential long-term value creation if clinical development succeeds
Risk Factors
- Preclinical results may not translate to human clinical efficacy
- IND may face delays or FDA feedback requiring additional data
- Competitive landscape could evolve with other CDK2 or degrader programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276859 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $11.26 | awaiting T+60 | — | $10.66 (−5.33%) |
Sep 30, 2026 27d ago | Press Release | $11.26 | awaiting T+60 | — | $10.66 (−5.33%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.66 (−32.15%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.66 (−54.60%) |
Jul 7, 2026 16w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.66 (−55.69%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.66 (−55.97%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.66 (−55.97%) |
Jun 29, 2026 17w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.66 (−55.95%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.66 (−52.18%) |
Jun 2, 2026 21w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.66 (−39.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers